Thomas Frank E
- SEC CIK
- 0001242616
In the past year, 1 open-market purchase filing worth $25.0K and no sales.
Current role at each company
- SPRO Spero Therapeutics, Inc.Directoras of Jun 25, 2026
- LRMR Larimar Therapeutics, Inc.Directoras of May 20, 2026
- ORTX Orchard Therapeutics plcSee Remarksas of Jan 24, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $25.0K
- 1 filing
- Sold
- –
- 0 filings
- Net
- +$25.0K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Thomas Frank E as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
LRMR Larimar Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 (view filing) | Feb 27 | 3 days | Thomas Frank EDirector | PPurchase | +5.00K | $5.00 | +$25.0K | +250.0%7.00K after | |
| Feb 15, 2024 (view filing) | Feb 14 | 1 day | Thomas Frank EDirector | PPurchase | +2.00K | $11.00 | +$22.0K | New position2.00K after |
ORTX Orchard Therapeutics plc
See Remarks1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 4, 2022 (view filing) | Apr 1 | 3 days | Thomas Frank ESee Remarks | PPurchase | +10.0K | $0.75 | +$7.50K | +23.8%52.1K after |